Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human HER2 Anticorps:
anti-Mouse (Murine) HER2 Anticorps:
anti-Rat (Rattus) HER2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal HER2 Primary Antibody pour IHC (p) - ABIN1687346
Park, Kang, Kim: Does background parenchymal enhancement on MRI affect the rate of positive resection margin in breast cancer patients? dans The British journal of radiology 2015
Show all 56 Pubmed References
Human Monoclonal HER2 Primary Antibody pour IHC (p) - ABIN1688892
Savci-Heijink, Halfwerk, Hooijer, Horlings, Wesseling, van de Vijver: Retrospective analysis of metastatic behaviour of breast cancer subtypes. dans Breast cancer research and treatment 2015
Show all 50 Pubmed References
Human Monoclonal HER2 Primary Antibody pour IHC (fro), IHC (p) - ABIN967459
Carraway, Cantley: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. dans Cell 1994
Show all 9 Pubmed References
Human Monoclonal HER2 Primary Antibody pour IHC (f), IHC (fro) - ABIN2688859
Rubin, Finstad, Wong, Almadrones, Plante, Lloyd: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. dans American journal of obstetrics and gynecology 1993
Show all 7 Pubmed References
Human Polyclonal HER2 Primary Antibody pour IHC - ABIN966279
Dittadi, Gion: More about: prognostic importance of low c-erbB2 expression in breast tumors. dans Journal of the National Cancer Institute 2000
Show all 6 Pubmed References
Human Polyclonal HER2 Primary Antibody pour IHC - ABIN966277
Marone, Hess, Dankort, Muller, Hynes, Badache: Memo mediates ErbB2-driven cell motility. dans Nature cell biology 2004
Show all 5 Pubmed References
Human Monoclonal HER2 Primary Antibody pour IF, IP - ABIN967787
Dillon, Creer, Kerr, Kümin, Dickson: Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain. dans Molecular and cellular biology 2002
Show all 5 Pubmed References
Human Monoclonal HER2 Primary Antibody pour IF, IP - ABIN967786
Piechocki, Pilon, Wei: Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. dans Journal of immunology (Baltimore, Md. : 1950) 2001
Show all 5 Pubmed References
Mouse (Murine) Polyclonal HER2 Primary Antibody pour DB - ABIN1881311
Cabodi, Tinnirello, Bisaro, Tornillo, del Pilar Camacho-Leal, Forni, Cojoca, Iezzi, Amici, Montani, Eva, Di Stefano, Muthuswamy, Tarone, Turco, Defilippi: p130Cas is an essential transducer element in ErbB2 transformation. dans FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010
Show all 5 Pubmed References
Human Polyclonal HER2 Primary Antibody pour DB, WB - ABIN1881305
Brandt, Mikesch, Simon, Rötger, Kemming, Schier, Sauter, Bürger: Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. dans Biochemical and biophysical research communications 2005
Show all 5 Pubmed References
MiR (Montrer MLXIP Anticorps)-193a-5p/ERBB2 have roles in response to chemoradiation therapy of esophageal squamous cell carcinoma
Trastuzumab treatment improves patients' survival regardless of HR status and should be offered to all HER2+ patients.
We aimed to investigate the prevalence, clinicopathologic characteristics, and functional relevance of novel HER2 mutations in breast cancer
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (Montrer IL6 Anticorps) (40.2pg/mL), VEGF-A (Montrer VEGFA Anticorps) (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (Montrer PRAP1 Anticorps) (248.1pg/mL), sHER-2/neu (5010pg/mL) and PLGF (Montrer PGF Anticorps) (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
data show that ErbB2 and Akt are important for CNC migration and implicate other ErbB receptors and Akt-independent signaling pathways. Our findings provide the first example of a functional interaction between the extracellular domain of a type II classical cadherin and growth factor receptors
The 12.5% overall overexpression/amplification or HER-2 in gastric and gastroesophageal junction adenocarcinomas is in concordance with previous reports. No correlation was found between tumor stage and HER2 overexpression/amplification. Determination of HER2 in limited tissue samples benefits from combinational immunohistochemistry and dual in situ hybridization testing.
Erb (Montrer ESR2 Anticorps)-b2 receptor tyrosine kinase (Montrer RET Anticorps) 2 (Montrer TYK2 Anticorps) gene (ERBB2/HER2) copy number gain was identified as a putative resistance mechanism to afatinib.
Our findings underline the survival benefit achieved by eribulin used according to European Union label in the overall metastatic breast cancer population and in various subgroups of interest, including patients with HER2-negative and triple-negative disease
Overall PIK3CA (Montrer PIK3CA Anticorps) mutant/HER2+ tumours had significantly lower pCR rates compared with wild-type tumours, however mainly confined to the HR+/PIK3CA (Montrer PIK3CA Anticorps) mutant population. No definite conclusions can be drawn regarding survival
Results suggest that our approach could provide a platform to develop nano-diagnostic agents or nano-therapeutic agents for early detection and treatment of HER-2-positive cancers.
YAP (Montrer YAP1 Anticorps) accumulated in nuclei of mammary glands in ErbB2/EGFR (Montrer EGFR Anticorps)-transgenic mice, suggesting that EGFR (Montrer EGFR Anticorps) signaling affects YAP (Montrer YAP1 Anticorps) in vivo similar to cell culture. ErbB2/EGFR (Montrer EGFR Anticorps)-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice.
Results indicate the importance of the LDL receptor (LDLR (Montrer LDLR Anticorps)) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN (Montrer PTEN Anticorps) is sufficient to shift isoform dependency from p110alpha (Montrer PIK3CA Anticorps) to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha (Montrer PIK3CA Anticorps) inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB (Montrer NUMB Anticorps) and NUMBL (Montrer NUMBL Anticorps) interacted with small GTPase (Montrer RACGAP1 Anticorps) Rab7 (Montrer RAB7A Anticorps) to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta (Montrer TGFB1 Anticorps), EGFR (Montrer EGFR Anticorps) and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR (Montrer EGFR Anticorps)-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB (Montrer EGFR Anticorps) receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS (Montrer IARS Anticorps) pathway in mouse breast cancer model.
Newly synthesized N-cadherin (Montrer CDH2 Anticorps) molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 (Montrer NRG1 Anticorps) is not the primary effector of trabeculation and/or that other EGF (Montrer EGF Anticorps)-like ligand(s) activates the ErbB2/ErbB4 (Montrer ERBB4 Anticorps) pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF (Montrer EGF Anticorps) family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT (Montrer AKT1 Anticorps) signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 (Montrer ERBB3 Anticorps) and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 (Montrer NRG1 Anticorps) and PI3K functionally interact with ErbB2 and ErbB3 (Montrer ERBB3 Anticorps) during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR (Montrer EGFR Anticorps)) and human epidermal growth factor receptor (Montrer EGFR Anticorps) 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2